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Screening, followed by colonoscopic polypectomy (or surgery for malignant lesions), 
prevents incident colorectal cancer and mortality. However, there are variations in effective 
application of nearly every aspect of the screening process. Screening is a multistep process, 
and failure in any of single step could result in unecessary morbidity and mortality. 
Awareness of variations in operator- and system-dependent performance has led to detailed, 
comprehensive recommendations in the United States nd Europe on how colonoscopy 
screening should be performed and measured. Likewise, guidance has been provided on 
quality assurance for non-primary colonoscopy-based screening programs, including 
strategies to maximize adherence. Quality improvement is now a validated science, and there 
is clear evidence that higher quality prevents incident cancer and cancer death. Quality must 
be addressed at the levels of the system, provider, and individuals, to maximize the benefits of 
screening for any population. We review the important spects of measuring and improving 
the quality of colorectal cancer screening.  
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Evidence-based quality assurance guidelines that cover the entire screening process and 
provide a list of key performance indicators and standards have been published by the 
European Union (EU) commission.1 Comprehensive documents that addressed colonoscopy 
quality were issued by the United States (US) Multi Society Task Force (MSTF) 2, by a 
special task force on quality 3, 4, and recently by the European Society for Gastrointestinal 
Endoscopy (ESGE). 5 Quality indicators for fecal immunochemical test (FIT) performance 
and follow up were also issued.6 A detailed evaluation of colonoscopy quality parameters is 
not feasible; we propose priorities for quality measurement in colorectal cancer (CRC) 
prevention and discuss proven methods to optimize these quality indicators.  
Several tests are available for CRC screening, but the most common options are FIT, 
colonoscopy, and sigmoidoscopy. Figure 1 lists proposed priority CRC screening quality 
measures for a healthcare delivery system. These measures relate to CRC screening 
adherence, colonoscopy (the primary screening method and preferred test for diagnostic 
analysis and post-polypectomy surveillance), and FIT. We discuss measures to evaluate CRC 
screening quality and methods to optimize these quality indicators. 
 
Maximizing Adherence to Screening and Diagnostic Colonoscopy Evaluations 
Screening programs have reduced CRC incidence, mortality, and surgery at the population 
level,7-9 but screening rates remain low in several countries. Screening rates are consistently 
low, independent of ethnicity and educational level, among the uninsured, individuals of low 
socioeconomic status, and individuals with limited access to primary care.10-13 Non-adherence 
to recommended protocols is an important attributable factor of CRC burden13 and the social 
gradient in screening uptake might increase disparities in mortality14. EU guidelines proposed 
acceptable and desirable adherence rates to CRC screening at greater than 45% and greater 
than 65%, respectively, and compliance with colonoscopy referral among persons undergoing 
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screening with a positive result from a primary screening test at above 90%.1 The National 
CRC Round Table15 proposed a 80% adherence target for primary screening a d the US 
Multi-Society Task Force on CRC US set a target of 80% compliance with colonoscopy 
referral in patients with a positive result from a FIT 6.  
 
CRC awareness 
Awareness of cancer, as well as of screening modalities, s an important factor in the decision 
to participate in CRC screening, in that it affects beliefs, attitudes, and motivation.16 
Addressing structural barriers at the health system and organization level might be required to 
increase participation rates, once awareness has been raised. Analyses of barriers to 
screening16 found a link between awareness and health system factors, such as public 
education and primary care physician efforts, and indicated that although individual 
knowledge and perceptions drive intentions to participate, issues related to practice 
organization are important to translate intention into action.17  
 
Therefore, the health system, and the context within which it is embedded, affects provider 
delivery and patient use of screening 18, 19 and compliance with cancer screening 
recommendations requires multifaceted interactions among patients, providers, and health 
organizations. Interventions that target multiple levels of care and consider factors outside the 
individual control of clinicians and integrate different strategies could be the most effective 
approach to increase uptake of CRC screening. 
 
System-level interventions 
Evidence for higher uptake rates and reduced coverage disparities regardless of socio-
economic status indicates that population-based organized programs, delivered at the national 
5 
 
level or by healthcare systems, can integrate interventions that address health system and 
individual-level barriers and help establish an organizational framework that gives each 
eligible subject a chance to participate.20 Organized programs produce higher rates of uptake, 
screening, and follow-up assessment than opportunistic screening. In the US, an organized 
program based on FIT screening achieved 83% adherence in a large healthcare system, 20 
whereas national measures of screening, which largely eflect the opportunistic setting in the 
US, have been stagnant in recent years at approximately 60%.21  
 
Higher screening rates and reduced coverage disparities by socioeconomic status have been 
reported in the EU, in areas where organized programs had been introduced, compared with 
areas where only opportunistic screening was available.20 System-level measures adopted 
within organized programs are establishing a suitable context to maximize the effects of 
interventions, targeting provider- and individual-re ated factors by reducing external barriers 
to the implementation of their decision to engage in screening.  
 
Financial barriers 
The type of insurance coverage and the cost of the test affect rates of screening and subjects’ 
preferences for specific tests. The introduction of free programs (funded by national or 
regional governments) and mandatory insurance coverage or elimination of cost sharing for 
screening and assessment tests, have increased the use of screening. Eliminating these 
economic barriers resulted in substantial increase (ranging from 7% to 50%, depending on 
background rates of use) in population coverage, in particular among the low-income, least-





Mailing personal invitation letters, at the recommend d intervals, to all eligible subjects, or 
sending electronic invitations,  is a widely adopted, highly effective, organizational measure 
to engage the target population. This approach is associated with screening uptake, 
irrespective of the test adopted (Figure 2).26 Cost-effectiveness is generally lower for client-
directed interventions, such as face to face counseling, telephone reminders, or navigators, 
than for strategies that involve mail or electronic i vitations or alerts.  Lower cost-
effectiveness reduces the sustainability and feasibility of those interventions in the context of 
large population-based programs.27, 28 However, direct invitation by primary care physician 
(PCP) is still a valid option, especially in settings with inadequate information technology 
infrastructure or limited use of mail or electronic reminders. The combined FIT and multi 
target stool DNA test is less cost effective than an ual FIT, but use of a telephone based 
navigation system resulted in 71% test completion in a Medicare population.29  
 
Type of screening test 
Multiple tests have been validated for CRC screening. These differ in effectiveness, 
acceptability, safety, and cost profile. Dislike of specific tests appears to be a barrier to CRC 
screening, so choice of the screening method pr vides an additional system-level factor that 
affects uptake. Introduction of the FIT was associated with an absolute increase in 
participation (increases ranging from 5% to 16%) in population-based programs 27, compared 
with the guaiac fecal occult blood test, likely relat d to the simpler testing procedure. 
Participation tends to be lower for invasive, endoscopic evaluations (absolute decrease in 
participation in a single round ranging from 2% to 30% for the FIT vs computed tomography 
colonography [CTC] and from 5% to 36% for FIT vs colonoscopy).27,30 Colonoscopy and 
sigmoidoscopy have the advantage that they bring a patient into compliance for long time 
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(more than 10—15 years when no neoplasia is detected), whereas adherence to repeated 
guaiac fecal occult blood tests or FITs decrease rapidly.31 
 
There are also sex differences in uptake of FIT vs endoscopy. Women have higher rates of 
participation when invited for a FIT (absolute difference between women vs men ranges from 
2% to 10%), whereas men have higher rates of response to invitations for endoscopy 
(absolute difference for men vs women ranges from 2% to 5%). Screening uptake did not 




High-quality evidence indicates that adoption of strategies to facilitate access to a 
recommended test,27 or reinforcement of motivation of subjects to attend,32 can increase 
subjects’ response to an invitation and affect individual-related barriers (Figure 2). Although 
studies assessing the specific contribution to screening uptake after distribution of information 
leaflets, in addition to an invitation letter, had inconsistent results33, the provision of 
educational material supports efforts aimed to promote informed participation. 34, 35 Leaflets 
can also provide information that is tailored to address barriers experienced by specific sub-
groups.  
 
Information material, designed to overcome language, literacy, or cultural barriers and 
developed based on theoretical models of behavioral change, mailed together with the 
invitation letter, as well as increased reminders, can increase overall uptake 36, 37 at a low cost. 
The observed absolute increase in uptake varied, ranging from 1% to 20%. In the study 
reporting the lowest effect, the intervention showed, however, a stronger effect in most 
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deprived groups, indicating that it might reduce th socioeconomic gradient in screening 
participation.36  
 
Primary care physicians 
Reports of PCPs demonstrated that provider’s involvement can improve compliance to 
primary screening invitations and recommendations fr diagnostic evaluation38, 39, particularly 
for less-educated, or older people, who are less likely to use written information material.40 
Changes in practice organization that aim to reduce the effects of commonly reported barriers 
related to lack of time and resources for preventiv care are effective measures to maximize 
the effects of providers’ efforts (Figure 2).  
 
Educational interventions that aim to foster knowledg  of program effectiveness, of the 
accuracy of the adopted method, and of the recommended screening procedures,41 as well as 
those that provide regular feedback about individual PCPs’ screening rates and their relative 
performance,42 can reinforce providers’ commitment to promotion of screening. Increasingly, 
practitioners are evaluated by their success in reaching adherence targets in the opportunistic 
setting, using available data from electronic medical records.  
 
Diagnostic colonoscopy after a positive result from a screening test 
Although adherence to primary screening is an important determinant of the magnitude of the 
health effects of screening at the population level, th  expected reduction of CRC burden can 
be only achieved if subjects with abnormal findings receive timely and appropriate follow up 
and treatment, if needed. However, although targets of at least 80% have been proposed, 
many persons who have positive results from screening tests (ranging from 8% to 34%, 
according to several reports) do not undergo the recommended assessment.13 Timeliness of 
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the follow-up examination is also important; 1 study showed that delays of greater than 10 
months for colonoscopies (compared with 8–30 days) were associated with a 2-fold increase 
in advanced stage cancer.43 
 
The lack of an established organizational infrastructure allowing for monitoring compliance 
with the recommended assessments, as well as difficulties in sharing data between clinical 
and screening services, have been reported as specific barriers to effective follow up of 
persons with positive results from screening.44 Economic (cost of the test and/or co-payment), 
organizational (limited endoscopic resources), and cultural (fear of the test and of cancer, 
fatalistic attitude) barriers, already documented for primary screening44 contribute to limit the 
response to colonoscopy referral following a positive results from screening tests. 
 
System-level interventions, including elimination of financial barriers for further 
investigations, and implementation of an active recall and fail-safe system, ensuring 
systematic assessment of all non-responders, were associ ted with an increase in the 
proportion of screen-positive individuals who received timely follow up.45 Providing tailored 
written information material, offering access to telephone or face to face counselling, 
addressing fears related to abnormal findings, patient-level navigation, and provider 
reminders increased compliance with colonoscopy refer al, maintaining a high cost-
effectiveness ratio also within organized programs.45 
 
Optimizing Colonoscopy Quality 
Colonoscopy is recommended as a primary screening method and it is a preferred diagnostic 
method for persons with positive results from other m thods, as well as for surveillance 
following polypectomy. For this reason, quality of colonoscopy is crucial to achieve the 
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expected benefit of screening, independent of the strategy adopted for primary screening. 
Therefore, it is important to discuss each key performance indicator of colonoscopy in detail. 
 
How to optimize bowel preparation for colonoscopy? 
The effects of inadequate bowel preparations on colonoscopy resources and costs are 
substantial 46. In addition, bowel preparation interacts with detection targets. Inadequate 
preparation therefore impairs detection and creates inefficiency 47, 48. In the US, the MSTF 
recommended that at least 85% of outpatient colonoscopies achieve adequate preparation 49, 
and the ESGE recommended 90% 50. Adequate preparation is best defined using clinical 
grading scales such as the Boston Bowel Preparation Scale, in which a score of 2 or more in 
each of 3 colonic segments is considered adequate51. Excellent and good preparations are also 
widely accepted as adequate 49; the MSTF states that a preparation that allowed detection of 
lesions larger than 5 mm is considered adequate 49.  In scoring rates of adequate preparation, 
the recommended colonoscopy follow-up interval must meet prevailing surveillance or 
screening recommendations to be scored in compliance 49. 
 
Over the last decade, the quality of bowel preparation for colonoscopy has greatly improved. 
Development and widespread implementation of validate  bowel preparation scales increased 
our understanding of variations in quality, set performance standards, and stimulated 
improvements.51-53 A true paradigm shift came from delivering the entir  dose the day before 
colonoscopy to split-dose or same-day regimens. This single change increased the rate of 
adequate bowel preparation from 63% to 85%.54 There is an inverse correlation between the 
degree of colon cleanliness and time between the last dose of bowel preparation and the start 
of colonoscopy.55 It is now recommended that the last portion of the bowel purgative be 




Another milestone was our increased understanding of the importance of oral and written 
instructions for bowel preparation. Enhanced instructions, consisting of visual aids, social 
media apps, telephone/short message service (SMS), and smartphone applications, were all 
proven to optimize bowel preparation57. These are now recommended as an adjunct to 
standard instructions.56 New low-volume bowel preparations might increase tol rability 
without compromising the efficacy of cleansing.56 Although bowel preparation is considered a 
barrier to CRC screening, lowering the dose of purgative does not seem sufficient to increase 
colonoscopy adherence rates.58  
 
How to optimize rates of cecal intubation? 
Cecal intubation is defined as the instrument tip passing the ileocecal valve and reaching fully 
into cecal caput, allowing detailed inspection of the mucosa between the ileocecal valve and 
appendiceal orifice. The cecal intubation rate (CIR) is a priority measurement—low CIR is 
associated with interval CRC (iCRC) 59. Recommended targets include more than 90% for all 
colonoscopies and more than 95% for screening colonoscopies 4, 5. Programs should audit the 
quality of documentation, including naming and photography of cecal landmarks—most 
importantly the appendiceal orifice 4. 
 
Competence in cecal intubation is usually achieved in the process of colonoscopy training 
since it is a key measure of skills acquisition.60 Nevertheless, in routine clinical practice, it is 
common for CIRs of individual endoscopists or practices to fall below the recommended 
standards.61-63 The first step in the process to optimize CIR is to measure and provide 
feedback on performance.64, 65 Quarterly report cards were shown to improve CIRs among 
experienced endoscopists.66 Other specific improvement interventions include optimization of 
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bowel preparation,64 provision of sedation,67, 68 use of adjuvant magnetic endoscopic 
imaging69, and additional training using novel competency asses ment tools.70, 71 An 
unresolved issue is whether continuous long-term measurement of CIR for colonoscopists 
who repeatedly demonstrate performance well above thresholds is productive—CIRs of 
individual colonoscopists are typically stable or increase over time. 
 
How to optimize lesion detection? 
The adenoma detection rate (ADR) was proposed as a quality indicator for colonoscopy in 
2002 by the MSTF. It is generally defined as the percentage of patients undergoing first-time 
primary screening colonoscopy who are 50 years or older and have 1 or more conventional 
adenomas detected 3, 4. The original definition did not restrict measurement to screening 2,
though recommended targets were based on screening studies. Recent studies have raised 
questions about the screening restriction, because scre ning ADR is intermediate between 
surveillance ADR (higher) and diagnostic examinations (which are lower, except for those 
performed for positive fecal blood tests) 72, 73. Recommendations for ADR include minimum 
acceptable thresholds, which were recently increased for primary screening in the US to 30% 
in men and 20% in women, 4 or 25% in mixed population, by the ESGE52 . Targets for 
individuals with a positive result from a FIT should be 15%–20% higher than for a primary 
screening population; these were recommended to be 45% for men and 35% for women by 
the MSTF6 . Adjustments based on patient population features such as better general health, 
obesity, cigarette smoking, etc, are unnecessary 74.  
 
The ADR target is not recommended to include sessil errated lesions (SSLs, also called 
sessile serrated polyps and sessile serrated adenomas). The rationale is the well-documented 
interobserver variation between pathologists in differentiation of SSLs from hyperplastic 
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polyps (HPs). In a recent clinical trial, ADR included both conventional adenomas and SSL 
75, but all lesions detected were reviewed by central expert pathologists. A separate detection 
target for SSLs has generated some interest, and coul be implemented at the institutional 
level 76, 77. One solution to the problem of differentiating SSLs from HPs is to create a SSL 
plus HP target. However, this target requires confini g the measurement to proximal colon to 
avoid incentivizing removal of diminutive HPs from the rectosigmoid. Intra- and inter-
observer variations among colonoscopists in identifyi g landmarks such as the splenic flexure 
and sigmoid descending colon junction make prospective accurate application of a target 
confined to the proximal colon unreliable. In general, the correlation between detection of 
conventional adenomas and various serrated detection targets has been high 77-83. Given the 
challenges of a separate serrated detection target, this correlation indicates that a continued 
focus on ADR in quality programs is reasonable.  
 
Although ADR is not an ideal quality parameter, it has been widely validated by studies 
reporting its association with iCRC84 and fatal iCRC.85 Alternative proposed measures, such 
as iCRC rates, adenoma and advanced adenoma miss rate , advanced adenoma detection rate, 
adenomas per colonoscopy, and polyp detection rate all have deficiencies, including issues 
such as lack of feasibility, requirement for tandem studies, a tendency to measure pathologist 
performance rather than endoscopist performance, or susceptibility to gaming when used 
prospectively.  
 
The benchmark of adenomas per colonoscopy (APC) 86 provides greater separation among 
endoscopists than the ADR87, 88 and avoids the theoretical concern about 1 and done (in which 
an endoscopist detects 1 adenoma and then performs a suboptimal examination of the 
remaining colon).89 Generally, ADR and APC correlate 87, 88. In the long term, converting 
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from ADR to APC appears to be advantageous, because APC measures the quality of 
colonoscopy over the complete examination, provided that APC is validated as a predictor of 
iCRC. Implementation of APC should be accompanied by agreement on handling procedures 
for multiple small and diminutive adenomas in the same colon section—placing them in 
separate containers for pathology examination would increase costs. Photography of multiple 
lesions to document the number of lesions, accompanied by the current practice of placing 
lesions of the same predicted histologic type and from the same segment of the colon in 1 
bottle, is could reduce the pathology costs with APC90. Regardless of using photography to 
assist in documentation of APC, routine photography of advanced lesions, including 
photographs before and after resection, is widely considered best documentation practice. 
 
Increases in ADR have been associated with reduced risk of iCRC and fatal iCRC.91, 65 
Therefore minimum thresholds should activate remediation when not reached 4. 
Colonoscopists with ADRs above recommended threshold  should also strive to improve their 
ADR,92  since CRC protection increases with ADRs above minimum thresholds. Although the 
target thresholds are unknown, colonoscopists could be reasonably recommended to aspire to 
ADRs of 40%–50% in primary screening92—the risk of iCRC continued to decrease to these 
levels of ADR.85 Remediation of low detectors requires multifaceted change of endoscopists 
behavior and examination technique, which can be coupled with improved imaging 
technology.93-95 Audit and performance-enhancing feedback seem have t e greatest effect in 
improving ADR,91, 96, 97 although not all programs have proven successful.98 The optimal 
frequency and method of providing feedback are unknown. A major focus should be put on 
examination technique, which could be deconstructed into 4 main components: looking 
behind all folds, cleaning residual stool, providing adequate bowel distension and 




Effective interventions to improve fold examination include double inspection of the right 
colon (either forward viewing or in retroflex)100 and use of mucosal exposure devices 
(Endocuff, Endorings, or G-Eye balloon). Of all mucosal exposure devices, the Endocuff is 
the most comprehensively studied and has the best evidence of efficacy.101, 102 Better cleaning 
of residual stool can be achieved by optimized cleansing regimens described earlier in this 
article or use of water exchange method.103  Successful bowel distension can be achieved by 
dynamic position changes during withdrawal.104 Application of effective examination 
techniques will consistently result in longer withdrawal times. Withdrawal time was originally 
recommended to average 6–10 minutes in normal colonoscopies, and then altered to 6 or 
more minutes.105 Detection of adenomas92 and probably also serrated lesions106  is optimized 
at a mean withdrawal time of 9 minutes. Short withdrawal times are a surrogate of poor 
examination technique, and indicate need for technique remediation for endoscopists with low 
ADRs. However, a policy of adequate withdrawal time as the primary quality indicator was 
unsuccessful.107 
 
Of the multiple imaging modalities developed to improve ADR, relatively few were proven 
effective in clinical practice. High-definition white-light imaging increased absolute ADR by 
3.5% compared with standard definition endoscopy.108 However, it might require more than 1 
change in instrument generation to increase ADR in practice.109, 110  Conventional 
chromoendoscopy increased ADRs by 6-7% compared with standard or high-definition white-
light colonoscopy, although chromoendoscopy adds 4–10 minutes to the procedure time and 
is considered too cumbersome to implement in clinical practice.111  A change from topical to a 
per oral multimatrix structure methylene blue formulation was recently reported to increase 
ADR by 8.5%.112  Electronic chromoendoscopy was generally considered ineffective,113 but a 
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recent meta-analysis showed that brighter-illumination narrow-band imaging increased 
ADRs, particularly when bowel preparation was excellent.114  Similarly, Fujinon has 
developed 2 forms of brighter-illumination electronic chromoendoscopy, called blue-light 
imaging and linked-color imaging; each increased ADRs in initial studies.115  
 
Optimizing rates of polyp resection 
Ineffective resection of precancerous lesions might contribute to iCRC.116 Rates of complete 
resection of lesions 5–20 mm varied 3-fold, 117 along with assessments of polypectomy 
competency. 118 Two scales have been validated for measuring resection skill.119, 120 The 
Direct Observation of Polypectomy Skills applies to small lesions and endoscopic mucosal 
resection.119 The Cold Snare Polypectomy Assessment Tool is usedsp cifically for cold 
snaring120 and is easily applied to routine colonoscopies.  Detailed recommendations on 
optimal resection technique were made by the ESGE.52, 121 
 
Lack of formal national guidelines and training courses in colorectal polypectomy or 
endoscopic mucosal resection are likely key reasons for high variability in competence and 
complete resection rates among endoscopists.118, 122 There is considerable variation and 
incompetency in polyp assessment, including its size123 and morphology124 as well as 
accuracy in positioning snare over the lesion and grasping an appropriate amount of tissue.118 
Use of structured competency scales (such as the Direct Observation of Polypectomy Skills or 
Cold Snare Polypectomy Assessment Tool) might improve polypectomy training.125 Lecture-
based training for gastroenterology fellows seems insufficient to increase polypectomy 
competence.126 Importantly, feedback and training in polypectomy performance, coupled with 
educational videos, improve polypectomy skills, especially for diminutive polyps.127 For 
polyps larger than 3 mm, emphasis on appropriate res ction technique using a snare instead of 
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biopsy forceps is crucial.52, 128 For larger lesions, priorities should include training with ex 
vivo models,129 appropriate number of procedures,130 and focus on en bloc resection of all 
pedunculated and non-pedunculated polyps up to 20 mm.116 The EU guidelines for quality 
assurance mandate that all endoscopists performing screening colonoscopies should be level 3 
competent in polypectomy, which includes removal of all pedunculated polyps and virtually 
all nonpedunculated polyps up to 20 mm.131  
 
How can we optimize post-polypectomy surveillance? 
Colonoscopy is overused in low-risk patients 132 and underused in high-risk patients.133 
Recommendations for screening and surveillance intervals should be monitored for 
consistency with published recommendations.134, 135  Adherence to post-polypectomy 
surveillance is low, with more than 50% of patients undergoing surveillance either too early 
or too late.136 The key to optimizing surveillance is to ensure that correct recommendations 
are given by gastroenterologists, surgeons, or family physicians, because these are the most 
important predictors of patient adherence.137, 138 Another solution is to integrate surveillance 
interval into electronic medical record system (to set reminders), so other provides can follow 
patients and refer them at proper intervals.139 
 
How Can We Optimize Screening Sigmoidoscopy? 
There is evidence that single sigmoidoscopy screens ca  reduce CRC incidence and mortality. 
However, data do not show an additional benefit of subsequent rounds of screening.140 There 
are many parallels in developing and monitoring quality ssurance in sigmoidoscopy 
programs to colonoscopy-based programs. Just like colonoscopy, there is high-quality 
evidence for wide variations in sigmoidoscopy performance141, 142, which translate into 
differences in cancer prevention143.  Important quality metrics for sigmoidoscopy include prep 
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quality, depth of insertion, and polyp detection. Recent studies reported the association of 
withdrawal times of at least 3.25 minutes and scope advancement to the splenic flexure with 
increased adenoma detection144.  Guidance regarding quality performance in sigmoidoscopy 
have been provided by some organizations145, 146. 
 
How Can We Optimize the FIT? 
There are important considerations for implementing high-quality FIT-based programs. For 
example, decisions must be made about the type of FIT (such as qualitative vs quantitative) to 
be used and the frequency with which it will be applied. Separately, decisions must be made 
about which FIT brand to use—if a quantitative platform is used, the numeric definition of a 
positive result must be established. Fortunately, there have been many articles published on 
these topics. Several large-scale national programs and clinical trials have produced findings 
that can be used in considering development of high-quality FIT based programs (see Table 
1).  
 
Optimizing patient preparation for the FIT 
Adherence increases the success of any CRC screening program, so programs should aim to 
simplify regular completion of FIT.  A significant advantage of the FIT, compared with the 
guaiac fecal occult blood test, is that the FIT directly measures hemoglobin in stool, and 
results are not affected by diet 147. So, to maximize adherence, no dietary changes should be 
recommended before stool collection. Similarly, simplifying recommendations about 
medications (such as aspirin and non-steroidal anti-inflammatory drugs [NSAID]) is also 
important. Hemoglobin degrades during gastrointestinal ransit, so drugs that cause upper 
gastrointestinal tract bleeding should not greatly ffect FIT results. Two recent meta-analyses 
found that NSAIDs and anticoagulants have little to no effect on test characteristics148, 149 and 
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support US multi-society task force recommendations not to stop taking NSAIDS before a 
FIT6. Direct-acting oral anticoagulants might reduce the positive predictive value of FIT to a 
significantly greater degree than conventional anticoagulants150, but further studies are 
needed.  
 
Optimizing choice of FIT and application 
There are qualitative and quantitative FITs. Qualitative tests have a visual indicator that 
indicates when there is hemoglobin in the sample, above a pre-set level. Quantitative tests rely 
on immunoturbidimetric methods and automated readings, i  which the cut-off value for a 
positive result can be set by the operator151. Quantitative tests have a number of advantages 
over qualitative tests; large national programs and clinical trials therefore often use the 
quantitative tests. There is evidence for significant variation in performance of qualitative 
tests152, and quantitative tests allow better matching of definitions of positive results to 
colonoscopy resources. For example, a screen program in The Netherlands changed a positive 
cut-off value from 15 to 47 ug Hb/g feces to improve positive predictive value and decrease 
colonoscopy burden153. However, in countries where colonoscopy resources ar  less limited, 
quantitative tests can facilitate application of the est to increase sensitivity.  In fact, in an 
analysis of 16 studies, a FIT threshold of 10 ugHB/g identified patients with colorectal cancer 
with 91% sensitivity and 90% sensitivity.154    
 
It is also important to determine how many FIT samples (1, 2, or 3) will be tested. Lower 
number of samples per cycle increase adherence. For example, in randomized controlled trials 
that compared results of FITs to 3-card conventional fecal occult blood tests, participation 
was more than 20% higher in the FIT group 155. In a recent population-based study over 4 
rounds that directly compared 1 FIT vs 2 FITs (on a biennial schedule), there was no 
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significant increase in diagnostic yield or decrease in interval CRC between the groups. 
Colonoscopy demand was higher in the 2-FIT group and the authors concluded that the 1-
sample FIT was the preferred approach.156  
 
A separate issue is whether to perform FITs on an annu l or biennial basis. Although annual 
screening, most population-based programs outside the US and 2 other trials of FIT vs 
colonoscopy used biennial testing (see Table 1).157Tradeoffs between the approaches include 
increased participant burden with more frequent application and delays in diagnosis of 
important lesions (such as advanced adenoma) with less frequent application. Differences in 
important outcomes including the overall number of p sitive results and detection of 
advanced neoplasia were not large, and programs have latitude in choosing the optimal 
approach within a population.158 
 
Optimizing FIT distribution and quality control  
Recent studies159-161 confirmed findings from earlier studies162-164 that positive results of FIT 
testing decrease in warmer months and might affect lesion detection. Programs are not 
currently considering season in FIT distribution, but do emphasize the importance of 
returning samples quickly. Improved FIT buffers arebeing developed, to prevent sample 
degradation.165 Quality control within the laboratory, including standardized result reporting, 
is required for program success.166, 167  Although the details are outside the scope of this 
review, a quality control program in The Netherlands investigated how changing collection 
devices, reagents, and laboratories affects positive results 168. FIT-based screening programs 
should track the percentage of kits received that cannot be processed; in the US, this value is 
recommended to be below 5%.6  Quality improvement efforts have been effective in reducing 
rates of laboratory-rejected samples.169  For example, placing red stickers on the FIT to 
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remind users of the need for rapid return increased rates of sample processing at the 
laboratory.   
 
New Screening Strategies Under Evaluation 
CTC is recommended for patients with positive results from a screening test who have 
contraindications to colonoscopy. The role of CTC as primary screening test is still under 
evaluation. Guidance for CTC quality has been published.170, 171 Although the details of those 
recommendations are beyond the scope of this review, some general statements can be made. 
High-quality colonic preparation, often with fecal t gging and adequate insufflation, is 
important for adequate test performance.  
 
With regard to imaging, use of multi-detector scanners is key, along with efforts to minimize 
radiation exposure. Although recommendations about primary mode of reading are generally 
not specific (such as starting with either the 2-dimensional or 3-dimensional rendering), it is 
clear that software should provide multiple display formats. Reporting should be 
standardized—the CT Colonography Reporting and DataSystem 170 is generally used for this 
purpose. Finally, it is important to use a data registry to track performance. The ability to 
regularly audit patient safety and outcome for use CTC is key, and performance indicators 
have been described.171, 172 
 
Multi-target DNA test 
MT-DNA test is available for only routine screening i  the US. The Food and Drug 
Administration approved this proprietary device (Cologuard; Exact Sciences, Madison WI) in 
2014 and the Center For Medicare and Medicaid Servic s provided payment coverage at a 
frequency of every 3 years.173  After an order is placed, the company directs the subsequent 
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distribution, receipt, processing, and results notification. Details regarding the laboratory 
methods and analytic use of the results have been dscribed.174  In brief, institutions or 
programs using this device would rely on the Exact Sciences laboratory for all quality control. 
 
Future Directions 
CRC screening reduces cancer-specific mortality and inci ence. The effectiveness of cancer 
screening, however, relies not only on the efficacy of screening test but also on the process of 
screening delivery, which includes adherence, quality of screening, and analysis of results. 
This complicated process requires monitoring and optimization of several steps. Screening 
programs create a perfect framework for comparative effectiveness research, in which 
screening optimization strategies can be tested. This framework includes joint database 
management systems, resources already allocated to potential interventions, and large 
numbers of potential participants.175, 176 Several aspects of CRC screening quality, such as 
rates of colonoscopy completion or adenoma detection, or adequacy of bowel cleansing, have 
been addressed. Others, such as variable and insufficient rates of adherence to screening, rates 
of complete endoscopic resection, and adequate post-polypectomy surveillance, are important 
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Figure 1. Summary of CRC screening quality measures and key optimization strategies. 
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